Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 8/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | DTYMK | P23919 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14341653 | 0.87 | HPGD (0.46) | HPGDL3MBTL1LMNACA12CA1 | |
| SCHEMBL14367054 | 0.80 | L3MBTL1 (0.41) | HPGDL3MBTL1LMNACA12CA1 | |
| SCHEMBL7518002 | 0.78 | MAPT (0.50) | HPGDL3MBTL1LMNAMAPTALDH1A1 | |
| SCHEMBL6208993 | 0.78 | NR1H2 (0.48) | HPGDL3MBTL1LMNACA12CA1 | |
| SCHEMBL4232728 | 0.76 | TPMT (0.41) | HPGDL3MBTL1LMNACA12CA1 | |
| SCHEMBL15694511 | 0.76 | CES2 (0.42) | HPGDL3MBTL1LMNACA1CA2 | |
| SCHEMBL9799523 | 0.76 | MAPT (0.55) | HPGDL3MBTL1LMNACA1CA2 | |
| SCHEMBL1157660 | 0.76 | MAPT (0.55) | HPGDL3MBTL1LMNACA1CA2 | |
| SCHEMBL28066049 | 0.76 | TSHR (0.46) | HPGDL3MBTL1LMNACA12CA1 | |
| SCHEMBL27311837 | 0.76 | HPGD (0.67) | HPGDL3MBTL1LMNAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058268-A1 | Compounds and methods for treating diabetic vascular diseases | CRABTREE ACQUISITION CO, LLC | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058268-A1 | Compounds and methods for treating diabetic vascular diseases | REN, SLC5A2, SLC5A1 | HPGD 379/4885L3MBTL1 4769/4885LMNA 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.